| Name | Title | Contact Details |
|---|---|---|
Ginny Reyes Llamzon |
Deputy General Counsel | Profile |
MedChemExpress offers a wide range of high-quality life science biochemicals, including novel bioactive compounds, recombinant proteins, dye reagents, peptides and natural compounds for laboratory and scientific use. We take pride in offering only the highest-grade products. Product identity, quality, purity and activity are assured by our robust quality control programs and procedures. We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.
RESRG Automotive is a global automotive supplier formed from the merger of Rehau Automotive and SRG Global Automotive, officially launched in April 2025. Headquartered in Troy, Michigan, with a European base in Rehau, Germany, the company operates 22 production sites across multiple countries, including Germany, France, and India. With a workforce of around 10,000 employees, RESRG projects pro-forma sales of €1.7 billion. The company specializes in polymer-based exterior and functional systems, offering products such as bumpers, grilles, lamp bezels, and roof panels. RESRG employs advanced manufacturing processes like injection molding and galvanizing, focusing on combining aesthetic appeal with functional performance. The company aims to partner with leading automakers to provide innovative solutions in automotive design and technology.
AI REV is a boutique AI consulting company with partners having extensive practical AI experience and strong track records. We provide state-of-the-art consulting & AI project delivery for enterprise clients. AI REVs goal is to reduce the average human workweek from 40 hours to 20. We are working towards achieving this by augmenting companies with AI-powered efficiency improvements. Our solutions have saved our customers up to 25% on related departamental costs, substantially decreased their operational risk, and enabled the reallocation of manpower to more pressing issues. We offer end-to-end Machine Learning, Data Science, AI & software development, Strategic Consulting, and Engineering Workshops.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.